INTRODUCTION
Proton-pump inhibitors (PPIs) such as omeprazole are one of the most widely prescribed classes of drugs worldwide. PPIs are indicated for treatment of ulcers with or without Helicobacter pylori infection; for treatment of gastroesophageal reflux, Zollinger-Ellison disease, dyspepsia, esophagitis and gastritis; and for prevention of peptic ulcers in patients receiving nonsteroidal inflammatory agents (NSAIDs) and in patients with upper gastrointestinal bleeding. 1 Therefore, they are medications that are ever-present in gastroenterologists' practice. 2 Omeprazole is effective and safe most of the time. 1 However, Mastroianni et al. 3 found that omeprazole was the drug most commonly associated with hospital admission, in a survey on the prevalence of hospitalizations due to adverse drug reactions. In addition, the safety of a drug may change over time through increased use and according to patients' characteristics. Therefore, risk assessment is required. 4 This context can be elucidated from reports on abusive use of omeprazole and irrational prescription of this drug. 4 Thus, there have been studies reporting on the risks (adverse events) of use of omeprazole, such as: (a) gastric proliferative changes; 5 (b) increased creatinine and urea levels, leading to acute interstitial nephritis [6] [7] [8] and increased risk of developing chronic kidney disease; 9 (c) increased risk of asthma concomitant with gastroesophageal reflux; 10 (d) increased risk of infection by Clostridium difficile; [11] [12] [13] (e) decreased absorption of vitamin B; 14 (f) steatorrhea caused by cystic fibrosis; 15 (g) fracture with decreased calcium absorption; 16, 17 (h) gynecomastia; 18 (i) hypomagnesemia; 19 (j) hyponatremia; 20 (k) spontaneous bacterial peritonitis; 21 l) pneumonia; 22 (m) anaphylactic reactions to omeprazole; 23 and (n) risk of celiac disease. 24 In addition, studies that evaluated the prevalence of hospital admission due to adverse drug events have cited omeprazole among the drugs that were possibly related to hospitalization, thus also suggesting that off-label use of omeprazole occurs frequently. 23, 24 Off-label use of drugs consists of their use for unapproved indications and usually occurs among polymedicated patients orcid.org/0000-0002-2905-8519
Side Effects and Adverse Reactions" OR "Risk Assessment" OR "Treatment Outcome" OR "Off-Label Use"). All descriptors used in these search strategies are Medical Subject Headings (MeSH terms). We included randomized clinical trials, phases I and II clinical trials, case-control studies, cohort studies, cross-sectional and quasi-experimental studies (clinical trials in which there was no comparator group for the intervention) evaluating adverse events from therapeutic or prophylactic use of omeprazole among individuals in all age groups whose health status was well defined and who were using omeprazole in an FDA-approved and/or off-label manner.
We excluded review articles, dissertations and theses, case reports, abstracts published in annals of events, editorials, letters to the editor, news and comments.
Selection process and data extraction

Types of participant
The target population comprised patients of any kind whose health status was well defined and who were using omeprazole in an FDA-approved and/or off-label manner. There was no age limitation.
Types of intervention
The interventions considered comprised use of omeprazole from the outset of treatment to clinical outcome, without restrictions on doses, therapeutic regimens or duration of use. In addition, it was proposed to include both preventive use and therapeutic use.
Types of outcome
The outcomes considered comprised any safety-related outcome, including adverse events, withdrawal due to adverse events, mortality and therapeutic ineffectiveness, i.e. adverse events in which the medicine used did not present any therapeutic response or its therapeutic response was lower than expected. Safety-related outcomes of all causes and omeprazole-related causes were considered. After selecting potential articles in the databases, the titles and abstracts were reviewed by verifying patient exposure to omeprazole. The following variables were defined during the screening of articles: indication of use; study design; patient's clinical condition;
clinical outcomes, including all types of adverse events relating to use of omeprazole; recommendations; author; and year of publication.
The severity of adverse events was classified as described by the World Health Organization. In this definition, severe adverse reactions are harmful effects that occur during drug treatment and which can result in death, be life-threatening or lead to persistent or significant disability, congenital anomaly, clinically important effects, hospitalization or prolongation of hospitalization. Non-serious adverse reactions also fall within the concept of severe adverse reactions. 29 The search for studies, selection of studies and extraction of data were performed by three authors, in triplicate independently, to avoid the presence of bias in the selection and exclusion of articles. In addition, the kappa function was applied to analyze the agreement rate.
Risk of bias assessment
For randomized clinical trials, risk of bias was evaluated using the Cochrane collaboration tool (RoB 1), 30 which is based on seven domains: random sequence generation, concealment of allocation, blinding of participants and professionals, blinding of outcome assessors, outcome completeness, selective reporting of outcomes and other sources of bias. Each domain is judged as presenting low risk of bias, uncertain risk of bias or high risk of bias.
For case-control and cohort studies, we used the Newcastle-Ottawa tool. This provides evaluations in three domains: selection, comparability and outcome for cohort studies; and selection, comparability and exposure for case-control studies. Each item that is identified as presenting low risk of bias is given a "'star". There is a maximum of one "star" for each item within the "selection" and "exposure/outcome" categories; and a maximum of two "stars"
for "comparability". Therefore, each study can be classified with a maximum of nine "stars", which corresponds to a low risk of bias.
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The cross-sectional and quasi-experimental studies included in this review were not evaluated, since there are no validated tools for analysis on these study designs.
RESULTS
A total of 5,500 potentially relevant studies were identified. After reading the titles and/or abstracts, 4,746 studies were excluded because they did not meet the inclusion criteria. Another 218
were duplicates, and thus 536 studies were examined further.
It was not possible to access 2 of these 546 studies, because one of them is no longer indexed in the database and the other does not provide for the option to purchase and access the article. Our attempts to contact the authors of these two studies were unsuccessful. After screening the remaining articles, 191 studies were found to be eligible for complete text reading. After reading in full, 119 were excluded because they did not meet the inclusion criteria. Thus, 72 articles were considered eligible for the safety assessment on use of omeprazole, since they included all the variables that were being analyzed (Figure 1 ).
The proportion of overall agreement (kappa) observed in relation to making final decisions (inclusion and exclusion) from the database that included the screened articles was 0.807 (confidence interval, CI: 0.658-0.957).
Among these 72 studies, 58 reported on adverse drug events (ADEs): 47 studies on adverse drug reactions (ADRs), 5 studies on drug interactions (DIs) and 6 studies on therapeutic ineffectiveness (Table 1) . 13,14,32-48, 60, 65-67 The duration of use of omeprazole ranged from 5 days to 11 years in these studies. Only one study evaluated the off-label use of omeprazole. 41 A relationship was observed between use of omeprazole and increased risk of severe adverse events, such as development of coronary disorders that might lead to death. 32, 39, 43, 62, 88, 94, 96, 101 Regarding the clinical outcomes of the studies, the safety (ADRs and DIs) and the therapeutic ineffectiveness can be correlated.
Among the 62 studies included, 39 studies reported on ADRs, with 28 potential events that were identified during the post-marketing phase in relation to omeprazole (spontaneous abortion, proliferative changes and chills, among others); 6 studies demonstrated the drug interactions between omeprazole and clopidogrel or mycophenolate mofetil; and 5 studies described the therapeutic ineffectiveness that occurred with omeprazole (Table 2) . 5, 13, 16, [32] [33] [34] [38] [39] [40] [41] [42] Among the 40 clinical trials included in the review, after riskof-bias analysis, it was found that eight were classified as presenting low risk of bias, 14 as having high risk of bias and 17 as having uncertain risk of bias. The 17 studies analyzed using the Newcastle-Ottawa scale had low risk of bias (Table 3) . 13, 16, 28, 32, 33, [35] [36] [37] [38] [39] 
DISCUSSION
This review allowed us to identify and update the most severe and prevalent ADEs relating to use of omeprazole, and our findings corroborate similar results found in other studies. 3, 4 Severe ADEs occurred in patients who underwent heart-related surgery or drug interventions, such as in situations of acute coronary syndromes or percutaneous coronary intervention, 75, 78, 96 or in cases of concomitant use of such medications. 76 These events were associated with concomitant use of omeprazole and clopidogrel, which caused inhibition of the antiplatelet effect of omeprazole, 83 due to competitive inhibition of CYP2C19. Headache, constipation, diarrhea, abdominal pain, back pain, flatulence, respiratory tract infection and maculopapular rash. [32] [33] [34] [35] [36] [37] Uncommon reaction (≥ 0.1% and < 1%) Eczematous eruption, insomnia, somnolence, urticaria, urticaria vasculitis and vertigo. 38 Rare reaction (≥ 0.01% and < 0.1%) Angioedema, arthralgia, muscle pain, erythema multiforme, weakness, metallic taste in the mouth, allergic reaction, Steven-Johnson's syndrome and thirst. 38 Post-marketing experience Unstable angina, increased risk of fractures, cancer, cystitis, ulcerative colitis, stomatitis, abnormal renal function, hypergastrinemia, decreased levels of vitamin B12, increased creatinine levels, hypomagnesemia.
14,39-43
Potential events not described in omeprazole monograph (n = 28)
Miscarriage, proliferative changes, increased levels of chromogranin A, increased levels of fibroblast growth factor 2, chills, cardiovascular events (myocardial infarction, heart failure, stroke, ischemic stroke, pulmonary embolism and thrombosis), scarlet fever, hyperglycemia, mononucleosis infection, gastrointestinal bleeding, nasopharyngitis, otitis media, loss of libido, rhinitis, dementia, metabolic syndrome and hepatic steatosis, low sperm motility, increased risk of fibrosis progression, cirrhosis, hepatic decompensation and development of hepatocellular carcinoma. [44] [45] [46] [47] [48] 60, [65] [66] [67] DI (n = 6)
Omeprazole and clopidogrel: cardiovascular death, myocardial infarction, inhibition of the effect of clopidogrel, increased leukocyte and platelet levels and increased brain adverse events. 75, 76 Omeprazole and acenocoumarol: increased anticoagulant effect of acenocoumarol. 77 Omeprazole and mycophenolate mofetil: reduced absorption of mycophenolic acid. 49 Efficacy TI (n = 5) Some patients did not respond to omeprazole therapy and continued with colitis symptoms and gastrointestinal discomforts. Omeprazole failed to control the gastric acidity of some patients.
13 Table 1 . Frequencies of adverse events resulting from indication of omeprazole that were reported in studies published up to 2016 ADE = adverse drug event; ADR = adverse drug reaction; DI = drug interaction; TI = therapeutic ineffectiveness. The frequency of adverse reactions was classified according to the leaflet of the reference drug product, except for the 28 studies for which there was no information on the leaflet. Cross-sectional studies (2)
ADR: Proliferative changes
Patients who underwent endoscopy and who had been using proton-pump inhibitors for at least 2 months ( Table 3 . Continuation Several drug interactions relating to omeprazole, especially with antiplatelet agents, are known. 78, 94 The non-serious events that have been described are diarrhea, headache and somnolence, relating to use of omeprazole concomitantly with the antiretroviral drug etravirine. 32 The severe adverse events that have been described comprise inhibition of the antiplatelet effects of drugs such as clopidogrel, which increases the risk of developing heart problems that may lead to death; and decreased absorption of mycophenolic acid, which leads to rejection of transplanted organs. 49 Nevertheless, it is not possible to say with certainty that the adverse events described in these studies occurred due to drug interactions with omeprazole, since some of the studies included did not present statistically significant results. 71, [94] [95] [96] In two studies in which omeprazole was added to dual antiplatelet therapy (a combination of clopidogrel and acetylsalicylic acid), it reduced the stomach pain resulting from this therapy and no risk was found in this combination. 95 Nonetheless, it is always necessary to monitor potentially dangerous drug combinations between omeprazole and clopidogrel, acetylsalicylic acid and mycophenolate mofetil, among others.
Regarding drug interactions, all patients may be exposed to their effects, regardless of age or clinical condition. However, some patients are more susceptible, such as those who already have some type of heart disease or the elderly, who commonly use polypharmacy.
Only 12 studies included elderly patients, and these studies reported occurrences of severe adverse events such as dementia, myocardial infarction, cardiovascular death, stroke and pulmonary embolism, among others. In the non-elderly population, the severe adverse events reported included myocardial infarction, stroke, death and pulmonary embolism, but no relationship between the severity or the frequency of events and the patients' age was observed from use of omeprazole. However, other authors have suggested that age is a factor that influences occurrences of adverse events. Varallo et al. 24 observed in a cross-sectional study that the elderly population had fewer ADEs than adults did, probably because doctors provide greater care and attention regarding pharmacotherapeutic management for patients of this age group, since there are other factors that increase the likelihood of ADEs, such as polypharmacy. Beijer and de Blaey 100 reported that the chances that elderly individuals would need to be hospitalized due to adverse drug reactions (ADRs) were four times higher than those of younger people (16.6% versus 4.1%). Additionally, in 2015, the American Geriatrics Society advised through the Beers criteria that unjustified use of PPIs among the elderly for more than eight weeks should be avoided, since exposure to such drugs increases the risks of infection by Clostridium difficile, bone loss and fractures. 13, 16, 101 Another factor that may have influenced the appearance of adverse events is the duration of use of omeprazole. Non-serious adverse events such as diarrhea, headache, flatulence and abdominal pain, among others, have been reported among patients taking omeprazole for short periods of time, i.e. from a few days of use to a maximum of two weeks. [32] [33] [34] [35] [36] 74 Severe adverse events have been reported among patients who used omeprazole for longer times, i.e. more than one month. 35-37, 54,57,60,63,65-67,70,71,74-76,70,95, In only one of the studies analyzed here was omeprazole prescribed for off-label use. 41 However, off-label prescription of omeprazole is widespread in many countries and there is a need to assess the safety of this use. We take the view that the duration of exposure is likely to increase the likelihood of adverse events, since polypharmacy alone is a risk factor for occurrences of adverse events. 24 Outcomes of therapeutic ineffectiveness and symptom worsening were identified. It was noted that some patients did not respond to omeprazole treatment 13, 32, 64, 70 and that for others, their symptoms worsened. 62 The most likely reason for such events would be high concentrations of acid in the stomach, which could cause gastroparesis, decrease absorption and, consequently, decrease the therapeutic effect of omeprazole.
Although most of the adverse events reported were already known, unexpected events such as dementia, 44 low-motility sperm, 46 miscarriage, proliferative changes, 5 increased levels of chromogranin A, 79 increased levels of fibroblast growth factor 2, 72 chills, cardiovascular events (myocardial infarction, heart failure, stroke, ischemic stroke, pulmonary embolism and thrombosis), 47 scarlet fever, hyperglycemia, mononucleosis infection, gastrointestinal bleeding, nasopharyngitis, otitis media, loss of libido and rhinitis have also been identified. 4, [65] [66] [67] 102 Because the associations between these adverse events and use of omeprazole are not fully understood, there is a need to carry out further studies to investigate the relationships between omeprazole and these events. If such associations are verified, they should be described in the package leaflet.
In addition, more recent studies have identified other adverse events, such as decreased vitamin B12 levels, 40 increased levels of creatinine 41 and hypomagnesia. 42 Use of omeprazole is considered safe in the following situations:
when it is not combined with antiplatelet drugs; when it is administered to replace H2 receptor antagonists in patients who are resistant to treatment with drugs of this class; when the most appropriate posology and dosage is established for each condition and patient;
and when omeprazole is used in conjunction with a combination of antibiotics to eradicate H. pylori and to treat esophagitis, among other situations.
94,102
Limitations of the present study
No a priori design was provided for this review and the languages were restricted to Portuguese, English and Spanish.
Gray literature was not included. However, its inclusion would be unviable and probably would not add to the results found, since this type of literature is characterized by incomplete and poorly constructed data.
No methods were used to assess the homogeneity or heterogeneity between the studies, and the risk of publication bias among the studies included was not assessed. Furthermore, no information regarding potential conflicts of interest in the primary studies included was available.
All the outcomes evaluated related to approved indications for use of omeprazole. Therefore, the data confirm that there is no evi- 
